Cell and gene therapy consulting firm Dark Horse Consulting Group has acquired BioTechLogic.
DHC — with operations in North America, Europe and APAC — is recognized for its unequaled depth of CGT expertise worldwide. Illinois-based BioTechLogic, a manufacturing and CMC consulting firm, will now become a division of DHC.
The combined organization will offer strategic advisory, operations, and technical consulting across the biopharma industry, creating a "powerhouse" in the biopharma consulting space, while retaining a critical focus on advanced therapies.
“This acquisition allows us to extend our client base into the domains of traditional biologics and vaccine development while further optimizing efficiencies of cost, timeline, and resources for our CGT customers," said Anthony Davies, DHC Founder and CEO. "We are excited to combine DHC’s ‘white glove’ strategic advisory services with BioTechLogic’s significant operational expertise and technical services."